EF Hutton Acquisition Co. I reiterated their buy rating on shares of Upexi (NASDAQ:UPXI – Get Rating) in a research report sent to investors on Monday morning, Benzinga reports. The firm currently has a $7.00 price objective on the stock.

Upexi Stock Performance

UPXI opened at $3.63 on Monday. The company has a current ratio of 1.60, a quick ratio of 1.08 and a debt-to-equity ratio of 0.36. The company's 50-day moving average is $4.46. Upexi has a 52-week low of $3.56 and a 52-week high of $6.08.

Insider Transactions at Upexi

In other Upexi news, CEO Allan Marshall acquired 12,000 shares of the stock in a transaction dated Friday, December 9th. The shares were purchased at an average price of $4.11 per share, for a total transaction of $49,320.00. Following the purchase, the chief executive officer now directly owns 2,557,778 shares of the company's stock, valued at $10,512,467.58. The acquisition was disclosed in a filing with the SEC, which is available at this link. Company insiders own 54.96% of the company's stock.

Upexi Company Profile

Upexi, Inc manufacture and sells various branded products in the health, wellness, pet, beauty, and other markets. The company was formerly known as Grove, Inc and changed its name to Upexi, Inc in August 2022. Upexi, Inc was incorporated in 2018 and is headquartered in Clearwater, Florida.

Featured Stories

• Get a free copy of the StockNews.com research report on Upexi (UPXI)
• Will Tesla Shares Rally If Musk Steps Down From Twitter?
• Can Chewy Fetch Double Digit Gains in 2023?
• 5 Down But Not Out Stocks To Watch For 2023
• Eli Lilly Expects Enduring Growth, Despite Immediate Challenges
• Madrigal Pharmaceuticals Stock Is Up 200% In One Day, Here's Why

Receive News & Ratings for Upexi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Upexi and related companies with MarketBeat.com's FREE daily email newsletter.